Fig. 1From: Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study Probabilistic sensitivity analysis. CE: Cost-effectiveness; QALY: Quality-adjusted life yearBack to article page